Schnieders Capital Management buys $3,172,712 stake in Amgen (AMGN)

Amgen (AMGN) : Schnieders Capital Management scooped up 350 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 18,400 shares of Amgen which is valued at $3,172,712.Amgen makes up approximately 1.74% of Schnieders Capital Management’s portfolio.

Other Hedge Funds, Including , Twin Capital Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 9,212 additional shares and now holds a total of 64,167 shares of Amgen which is valued at $11,064,316. Amgen makes up approx 0.80% of Twin Capital Management Inc’s portfolio.Woodstock Corp reduced its stake in AMGN by selling 50 shares or 0.42% in the most recent quarter. The Hedge Fund company now holds 11,970 shares of AMGN which is valued at $2,075,957. Amgen makes up approx 0.41% of Woodstock Corp’s portfolio.Ausdal Financial Partners reduced its stake in AMGN by selling 260 shares or 7.74% in the most recent quarter. The Hedge Fund company now holds 3,101 shares of AMGN which is valued at $533,465. Amgen makes up approx 0.27% of Ausdal Financial Partners’s portfolio.Simplex Trading reduced its stake in AMGN by selling 6,632 shares or 19.33% in the most recent quarter. The Hedge Fund company now holds 27,673 shares of AMGN which is valued at $4,517,617. Amgen makes up approx 0.57% of Simplex Trading’s portfolio.Mai Capital Management reduced its stake in AMGN by selling 8,810 shares or 10.6% in the most recent quarter. The Hedge Fund company now holds 74,325 shares of AMGN which is valued at $12,109,772. Amgen makes up approx 0.97% of Mai Capital Management’s portfolio.

Amgen opened for trading at $171.48 and hit $174.72 on the upside on Monday, eventually ending the session at $174.58, with a gain of 0.90% or 1.56 points. The heightened volatility saw the trading volume jump to 27,84,334 shares. Company has a market cap of $130,649 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.